Consultation
Health Health
Pharmac proposes funding prasugrel again to widen heart treatment choice
The plan would increase treatment choice for around 4000 people at risk of serious heart-related events.
Pharmac wants public feedback on a plan to fund prasugrel for people who have had a heart attack or certain heart procedures.
Pharmac says the plan would give around 4000 people at risk of serious heart-related events more choice. Prasugrel was funded in New Zealand before, but its supplier discontinued it in 2021.
“This proposal would make the medicine available again and increase treatment choice for around 4000 people at risk of serious heart-related events,” said Michaela Lion, Pharmac’s Manager, Pharmaceutical Funding.
Lion explained that medicines suit people differently. For some, the treatments already funded may not be suitable because of allergy, intolerance or reduced effectiveness.
Prasugrel is used with aspirin. It helps prevent blood clots and related events such as heart attack and stroke in people with acute coronary syndrome. It is also for people having a percutaneous coronary intervention, such as coronary angioplasty or stent placement.
Pharmac proposes to fund prasugrel tablets in 5 milligram and 10 milligram strengths. They would be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 February 2027.
The tablets would be available in the community and in Health New Zealand | Te Whatu Ora (Health NZ) hospitals. Pharmac notes that prasugrel is taken once a day, which may make treatment easier for some people.
Pharmac gives the pronunciation as PRASS-you-grel.